Benefits
Testosterone Support (Mixed Evidence)
Initial trial (Reprod Biol Endocrinol) reported D-aspartic acid 3 g/day for 12 days increased testosterone ~42% in men with sub-optimal baseline T. Critical: subsequent RCTs in resistance-trained men with normal-to-high baseline T have been negative (Willoughby 2013; Melville 2017 — even reported T decreases at high doses). Population matters substantially; DAA is not reliable for athletic T enhancement.
Sperm Quality (Limited Evidence)
Some trials in subfertile men reported improved sperm count and motility. Evidence remains limited; standard fertility evaluation (semen analysis, hormonal workup, urology consultation) is foundational.
Urea Cycle (L-Aspartate)
L-Aspartate provides one of the two nitrogen atoms of urea, contributing to ammonia detoxification. Endogenous synthesis adequate under normal circumstances.
Neurotransmitter Function (L-Aspartate)
L-Aspartate is an excitatory neurotransmitter — activates NMDA and AMPA receptors. Important for synaptic plasticity, learning, and memory.
Mineral Chelation (Aspartate Salts)
Magnesium aspartate, potassium aspartate, zinc aspartate — well-tolerated mineral chelate forms used in many supplements. The aspartate carrier improves absorption vs inorganic salts.
Mechanism of action
D-Aspartate in Neuroendocrine Tissues
D-Aspartic acid is concentrated in pituitary, hypothalamus, testis, pineal gland. Stimulates GnRH release from hypothalamus → LH from pituitary → testosterone from Leydig cells. Also acts directly on testis. Mechanism reasonable but clinical effect inconsistent.
Urea Cycle (L-Aspartate)
L-Aspartate condenses with citrulline (catalyzed by argininosuccinate synthetase) to form argininosuccinate — provides nitrogen for urea cycle ammonia detoxification.
Glutamate/Aspartate Interconversion
Aspartate aminotransferase (AST/SGOT — clinical liver enzyme) interconverts aspartate ↔ oxaloacetate, integrating amino acid metabolism with TCA cycle.
NMDA Receptor Activation (L-Aspartate)
L-Aspartate is an agonist at NMDA glutamate receptors — excitatory neurotransmission. Less potent than glutamate.
Clinical trials
Initial clinical trial of D-aspartic acid 3,120 mg/day vs placebo in 23 men aged 27-37 with low baseline testosterone for 12 days. (Reprod Biol Endocrinol)
23 men with low-normal baseline T.
DAA reportedly increased serum testosterone ~42% vs placebo. Critical caveat: small trial; specific population (men with low baseline T); short duration; subsequent rigorous trials in different populations have not replicated.
Clinical trial of DAA 3 g/day vs placebo in 20 resistance-trained men over 28 days. (Willoughby &, Nutr Res)
20 resistance-trained men (normal-to-high baseline T).
Primary endpoint negative: NO significant difference in testosterone or strength between DAA and placebo groups. Important rigorous negative trial — substantially deflates DAA marketing claims for athletes.
Clinical trial examining DAA at 3 g/day and 6 g/day vs placebo in resistance-trained men over 14 days. (Nutrients)
Resistance-trained men.
Primary endpoint negative — and harm signal: 6 g/day DAA group had decreased serum testosterone vs placebo. Suggests DAA may decrease T at higher doses or in normal-T populations. The 'more is better' supplement marketing approach actively counterproductive.